Strand Life Sciences secures Indian patent for blood-based early cancer detection technology

image credit- freepik

Bengaluru-based Strand Life Sciences has announced the grant of an Indian patent covering its integrated platform for early cancer detection using cell-free DNA (cfDNA) analysis.

The patented platform brings together high-quality sequencing, rigorous quality control, biologically informed methylation and fragmentomic feature extraction, and machine learning to enable cancer detection and tissue-of-origin prediction from just a blood sample.

Widespread methylation pattern changes across the genome are a hallmark of cancer. A key innovation in the patent, among others, is obtaining these methylation patterns using genome sequencing with minimal loss or failure, thus enabling sensitive early cancer detection. 

"We believe this innovation represents an important step towards making precision cancer screening more accurate, scalable, and accessible," said Ramesh Hariharan, CEO, Strand Life Sciences. 

The granted patent further strengthens the company's intellectual property portfolio in liquid biopsy and reinforces its strategy of developing integrated, AI-enabled molecular approaches for early cancer detection and precision oncology.